Search Results
Your search for The ,The matches 34685 pages
Showing 34651 - 34685Breast Cancer Patients’ Fear of Developing Lymphedema Far Exceeds Risk
Women who have had the lymph nodes under their arm surgically removed during breast cancer treatment are warned to avoid certain practices that can cause lymphedema. Now, a new study published in the March issue of the Journal of the American College of Surgeons suggests that the vast majority of...
FDA Approves Regorafenib for Advanced Gastrointestinal Stromal Tumors
The FDA has expanded the approved use of regorafenib (Stivarga) to treat patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) that no longer respond to treatment with imatinib (Gleevec) or sunitinib (Sutent). Regorafenib, a multikinase inhibitor, blocks several enzymes...
FDA Approves New Treatment for HER2-positive, Metastatic Breast Cancer
The FDA approved ado-trastuzumab emtansine (Kadcyla), referred to as T-DM1 during clinical research, for patients with HER2-positive, metastatic breast cancer who were previously treated with trastuzumab (Herceptin) and taxane chemotherapy. “[Ado-trastuzumab emtansine] is trastuzumab...
Researchers Identify Variations in Four Genes That Are Associated with an Increased Risk of Colorectal Cancer
An international research team co-led by cancer prevention researcher Ulrike Peters, PhD, MPH, and biostatistician Hsu Li, PhD, at Fred Hutchinson Cancer Research Center has identified variations in four genes that are linked to an increased risk of colorectal cancer. Dr. Peters and...
Inaugural Winners of the Breakthrough Prize in Life Sciences Announced
Founding sponsors Art Levinson, PhD, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner announced the launch of the Breakthrough Prize in Life Sciences, recognizing excellence in research aimed at curing intractable diseases and extending human life. The prize will be...
New Drug Combination Could Prevent Head and Neck Cancer in High-risk Patients
A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal...
Selumetinib Shown to Reverse Radioiodine Resistance in Some Advanced Thyroid Cancers
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine, the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the February 14 issue of the New England...
New Website Raises Awareness of Uveal Melanoma and the Importance of Prognostic Testing
Launch of a website created to educate newly diagnosed patients, their families, and health-care providers about uveal melanoma, was announced recently by Castle Biosciences, Inc, a developer of prognostic tests for rare cancers. The website, MyUvealMelanoma.com, addresses the treatment of uveal...
Risk of Leukemia After Cancer Chemotherapy Persists
While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of...
Selumetinib Reported to Benefit Patients with Recurrent Low-grade Ovarian Cancer
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, but the disease is exceptionally difficult to treat when front-line therapy fails. "After surgery, with or without presurgical chemotherapy, when low-grade serous ovarian cancer persists or returns,...
AACR Hosts Congressional Briefing on Cancer Progress, NIH Funding
The American Association for Cancer Research (AACR) hosted a briefing on February 12 for members of Congress and their legislative staffs that highlighted progress in cancer research and treatment as well as challenges created by decreased levels of funding. The briefing was held in the Rayburn...
Triple-negative Breast Cancer Subtypes Identified Using MicroRNA
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy. The findings, by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and...
FDA Approves Pomalidomide for Advanced Multiple Myeloma
The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...
Experimental Drug Combination Selectively Destroys Lymphoma Cells
Laboratory experiments conducted by researchers at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the investigational agent ibrutinib and bortezomib (Velcade) could potentially be an effective new therapy for several forms of blood cancer, including...
Researchers Discover Mutations Linked to Relapse Of Childhood Leukemia
After an intensive 3-year hunt through the genome, researchers have pinpointed mutations that lead to drug resistance and relapse in acute lymphoblastic leukemia (ALL) ,the most common type of childhood cancer—the first time anyone has linked the disease’s reemergence to specific...
Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...
Yale Researchers Identify Genes behind Aggressive Endometrial Cancer
In a major breakthrough for uterine serous carcinoma (USC), a chemoresistant, aggressive form of endometrial cancer, researchers at Yale Cancer Center have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. The collaborative team, which included...
NCI Researchers Identify Molecular Link between Metabolism and Breast Cancer
A protein associated with conditions of metabolic imbalance, such as diabetes and obesity, may play a role in the development of aggressive forms of breast cancer, according to new findings by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their...
High-dose Vorinostat Effective at Treating Relapsed Lymphomas, Study Finds
Reporting the results of a phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of vorinostat (Zolinza) in combination with another round...
FDA Approval of Generic Version of Liposomal Doxorubicin Injection Is Expected to Help Resolve Shortage
The FDA has approved the first generic version of liposomal doxorubicin (Doxil), which is currently on the FDA’s drug shortage list. For products on the shortage list, the FDA’s Office of Generic Drugs is using a priority review system to expedite the review of generic applications to...
Less Invasive Treatment Is Associated with Improved Survival in Early-stage Breast Cancer
Patients with early-stage breast cancer who were treated with lumpectomy plus radiation may have a better chance of survival compared with those who underwent mastectomy, according to Duke Medicine research. The study, which appeared online January 28, 2013, in the journal Cancer, raises new...
MD Anderson Study Finds Qigong Improves Quality of Life for Breast Cancer Patients Undergoing Radiation Therapy
Researchers from The University of Texas MD Anderson Cancer Center have found qigong, an ancient mind-body practice, reduces depressive symptoms, and improves quality of life in women undergoing radiotherapy for breast cancer. The study, published in the journal Cancer, is the first to examine...
Alex’s Lemonade Stand Foundation Introduces Centers of Excellence Program to Further Childhood Cancer Research
Alex’s Lemonade Stand Foundation (ALSF), a registered 501(c)(3) charity, is furthering its commitment to finding cures for all children with cancer by introducing the ALSF Centers of Excellence program. The Centers of Excellence program aims to fund the research of leading childhood cancer...
Imatinib Receives New Indication for Children with Acute Lymphoblastic Leukemia
The FDA approved a new use of imatinib (Gleevec) to treat children newly diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). ALL is the most common type of pediatric cancer, affecting approximately 2,900 children annually, and progresses quickly if untreated....
Bevacizumab Approved as Combination Therapy for Metastatic Colorectal Cancer after Progression on First-line Bevacizumab Therapy
On January 23, 2013, the FDA approved bevacizumab (Avastin) for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-containing...
Researchers Discover Promising Prognostic Marker for Aggressive Breast Cancer
A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of...
Nab-paclitaxel plus Gemcitabine Demonstrates Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer
Celgene International Sàrl announced on Tuesday that its phase III clinical trial of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abaraxane) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer...
Genetic Basis of High-risk Childhood Cancer Points to Possible New Drug Treatment Strategy
Research led by St. Jude Children’s Research Hospital scientists has identified a possible lead in treatment of two childhood leukemia subtypes known for their dramatic loss of chromosomes and poor treatment outcomes. The findings also provide the first evidence of the genetic basis for ...
New Model May Help Predict Response to Chemotherapy for Colorectal Cancer
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, ...
Patients with NSCLC Have Improved Survival If They Use Beta-blockers While Receiving Radiotherapy
Patients with non–small cell lung cancer (NSCLC) have improved survival outcomes if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients recently published in Annals of Oncology. Researchers at the University of Texas MD Anderson Cancer Center in...
Ezatiostat Gets Orphan Designation for Treatment of Myelodysplastic Syndrome
Telik, Inc, announced that its product candidate, ezatiostat hydrochloride (Telintra), has been granted orphan drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS). Ezatiostat is an investigational agent in development for the treatment of MDS and idiopathic chronic...
Report to the Nation Shows U.S. Cancer Death Rates Continue to Drop
The Annual Report to the Nation on the Status of Cancer, 1975–2009, shows that overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites, including lung, colon and...
Dune Medical Devices Receives FDA Approval for the MarginProbe System
Dune Medical Devices, Inc, announced that the FDA has granted Premarket Approval to the MarginProbe System, the company’s breakthrough intraoperative tissue assessment tool for early-stage breast cancer surgery. The technology significantly improves surgeons’ ability to intraoperatively ...
Optimizing the Treatment of Acute Kidney Injury Caused by High-Dose Methotrexate: Integrating New Guidelines to Improve Patient Care
Patients receiving high-dose methotrexate (HDMTX) are at risk of developing acute kidney injury (AKI) due to delayed methotrexate clearance. New consensus guidelines aim to help the healthcare team optimize the treatment of AKI due to HDMTX and understand at which time points glucarpidase is most...
Improving Outcomes for Patients With Non–Small Cell Lung Cancer
For over a decade, the treatment landscape of non–small cell lung cancer (NSCLC) has been rapidly evolving. It now includes testing for genetic alterations and the use of targeted therapies and immunotherapies, with new targets and treatments still being discovered and approved. In this six-part...
